Key result
Epstein-Barr virus is present in ~58% of Burkitt lymphoma patients worldwide.
Why the study?
Estimating the prevalence of Epstein-Barr virus may help predict whether a population is at high risk of increased Burkitt lymphoma cases.
What is the prevalence of Epstein-Barr virus in patients with Burkitt lymphoma?
Meta-Analysis (n=4,837)
Yes
What is the prevalence of Epstein-Barr virus in patients with Burkitt lymphoma?
EBV is present in more than half of patients with Burkitt lymphoma, suggesting EBV testing could assist in predicting and assessing clinical disease status.
No takes yet. Share an insight, caveat, or question.
Supports EBV testing to assess Burkitt lymphoma status; extends prior estimates with worldwide pooled data.
Al‐Khreisat et al. (2023) conducted a meta-analysis in Burkitt lymphoma (n=4,837). Epstein-Barr virus was evaluated on Prevalence of Epstein-Barr virus (95% CI 51.5 to 63.4). Epstein-Barr virus was present in 57.5% (95% CI: 51.5 to 63.4) of patients with Burkitt lymphoma worldwide.